CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1.9%

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price traded up 1.9% during trading on Tuesday . The company traded as high as $72.44 and last traded at $72.40. 223,278 shares were traded during mid-day trading, a decline of 89% from the average session volume of 1,971,836 shares. The stock had previously closed at $71.08.

Analyst Ratings Changes

Several research analysts have recently commented on CRSP shares. Chardan Capital lifted their price objective on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Royal Bank of Canada lifted their price target on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 22nd. Wells Fargo & Company lifted their target price on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Needham & Company LLC raised their target price on CRISPR Therapeutics from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Finally, TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $74.75.

CRISPR Therapeutics Trading Down 1.1 %

The stock’s fifty day moving average price is $73.75 and its 200 day moving average price is $61.71.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, beating the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. CRISPR Therapeutics had a negative return on equity of 8.09% and a negative net margin of 240.84%. CRISPR Therapeutics’s revenue was up 3253.3% compared to the same quarter last year. During the same period last year, the firm posted ($1.41) earnings per share. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Activity

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares in the company, valued at $4,570,747.57. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,801 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $219,206.26. Following the completion of the transaction, the general counsel now directly owns 60,070 shares in the company, valued at $4,701,078.20. The disclosure for this sale can be found here. Insiders sold 134,410 shares of company stock valued at $9,234,677 over the last three months. Insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently added to or reduced their stakes in the business. CWM LLC grew its position in shares of CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares during the period. Tradewinds Capital Management LLC lifted its position in CRISPR Therapeutics by 545.5% during the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after purchasing an additional 600 shares in the last quarter. Blue Trust Inc. bought a new stake in CRISPR Therapeutics during the fourth quarter valued at about $32,000. Headlands Technologies LLC purchased a new stake in CRISPR Therapeutics in the third quarter worth about $34,000. Finally, Bourgeon Capital Management LLC raised its stake in shares of CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after buying an additional 500 shares during the period. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.